

**S4 Table.**  $^1\text{H}$  NMR data of the newly synthesized PfFNT inhibitors

Compound	$^1\text{H}$ NMR (300 MHz, 25 °C, $[\text{D}_6]\text{DMSO}$ )
[10]	$\delta$ 8.97 (s, 1H), 7.74 (d, $^3J = 8.8$ Hz, 1H), 6.76 (dd, $^3J = 8.8$ Hz, $^4J = 2.4$ Hz, 1H), 6.59 (d, $^4J = 2.4$ Hz, 1H), 3.85 (s, 3H), 3.37 (d, $^2J = 16.6$ Hz, 1H), 2.85 (d, $^2J = 16.6$ Hz, 1H)
[12]	$\delta$ 9.09 (s, 1H), 7.82 (d, $^3J = 8.3$ Hz, 1H), 7.30 (d, $^4J = 2.0$ Hz, 1H), 7.27 (dd, $^3J = 8.3$ Hz, $^4J = 2.0$ Hz, 1H), 3.50 (d, $^2J = 16.6$ Hz, 1H), 2.93 (d, $^2J = 16.6$ Hz, 1H)
[13]	$\delta$ 8.88 (s, 1H), 7.72 (d, $^3J = 8.8$ Hz, 1H), 6.73 (dd, $^3J = 8.8$ Hz, $^4J = 2.4$ Hz, 1H), 6.59 (d, $^4J = 2.4$ Hz, 1H), 4.13 (q, $^3J = 7.0$ Hz, 2H), 3.35 (d, $^2J = 16.5$ Hz, 1H), 2.81 (d, $^2J = 16.6$ Hz, 1H), 1.33 (t, $^3J = 7.0$ Hz, 3H)
[14]	$\delta$ 8.85 (d, $J = 0.7$ Hz, 1H), 7.72 (d, $^3J = 8.8$ Hz, 1H), 6.72 (dd, $^3J = 8.8$ Hz, $^4J = 2.4$ Hz, 1H), 6.57 (d, $^4J = 2.4$ Hz, 1H), 4.78 (m, 1H), 3.33 (d, $^2J = 16.6$ Hz, 1H), 2.81 (d, $^2J = 16.6$ Hz, 1H), 1.28 (dd, $^3J = 6.0$ Hz, $^4J = 2.1$ Hz, 6H)
[15]	$\delta$ 8.91 (s, 1H), 7.75 (d, $^3J = 8.7$ Hz, 1H), 7.49 – 7.31 (m, 5H), 6.83 (dd, $^3J = 8.7$ Hz, $^4J = 2.4$ Hz, 1H), 6.72 (d, $^4J = 2.3$ Hz, 1H), 5.23 (s, 2H), 3.37 (d, $^2J = 16.5$ Hz, 1H), 2.83 (d, $^2J = 16.5$ Hz, 1H)
BH-296	$\delta$ 13.24 (br s, 1H), 8.13 (m, 2H), 7.10 (m, 2H), 6.99 (s, 1H), 3.88 (s, 3H)
BH-296 prodrug	$\delta$ 7.92 (m, 2H), 7.09 (m, 2H), 6.82 (s, 1H), 3.95 (q, $^3J = 7.0$ Hz, 2H), 3.86 (s, 3H), 1.15 (t, $^3J = 7.0$ Hz, 3H)